Abpro Holdings, Inc.

Abpro Holdings, Inc., trading under the ticker ACAB, is a clinical-stage biopharmaceutical company that completed its business combination with Atlantic Coastal Acquisition Corp. II, a blank-check company sponsored by Atlantic Coastal Acquisition Management II LLC that conducted its IPO in 2022. The company focuses on the discovery and development of antibody-based therapeutics targeting oncology and other serious diseases. The August 2024 8-K filing reflects continued post-merger corporate activity for the combined entity, which operates in the life sciences and biotechnology sector. Investors and analysts tracking SPAC-derived biotech names can find comprehensive filing timelines, sponsor profiles, and deal histories for ACAB and hundreds of other transactions on SpacDesk — sign up at SpacDesk for full access to the data.